The peer-reviewed data on both the Moderna and Pfizer/BioNTech COVID vaccines are in, demonstrating 94% to 95% protection from the disease.The phase 3 clinical trial results for the Moderna COVID-19 vaccine, mRNA-1273, and the Pfizer/BioNTech COVID-19 vaccine, BNT162b2 or Comirnaty, were published late last week in the New England Journal of Medicine (NEJM).
When compared with placebos, Moderna's vaccine showed 94.1% efficacy (95% confidence interval [CI], 89.3% to 96.8%), and Pfizer's had 95.0% efficacy (95% CI, 90.3% to 97.6%).Both rates are for patients who received the two intended doses.
Adverse events were uncommon in both studies."That the mRNA-1273 Covid-19 and the BNT162b2 Covid-19 vaccines protect with near-identical 94 to 95%